Page last updated: 2024-11-10

acipimox

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

acipimox: lipolysis inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5310993
CHEMBL ID345714
CHEBI ID94688
SCHEMBL ID48922
MeSH IDM0089804

Synonyms (77)

Synonym
AC-009
AB01274727-01
AB01274727-02
gtpl1596
olbemox
k-9321 ,
olbetam
5-methylpyrazine-2-carboxylic acid 4-oxide
5-methyl-2-pyrazinecarboxylic acid 4-oxide
5-methylpyrazinecarboxylic acid 4-oxide
D07190
51037-30-0
acipimox (inn/ban)
acipimox
NCGC00160519-01
NCGC00160519-02
HMS2090G05
nsc-759818
CHEMBL345714 ,
bdbm50208130
5-methyl-4-oxy-pyrazine-2-carboxylic acid
5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid
2-carboxy-5-methylpyrazine 4-oxide
M2053
STK711089
tox21_111868
tox21_112805
dtxcid0026202
dtxsid2046202 ,
tox21_112498
cas-51037-30-0
5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic acid
A828409
BBL009924
pharmakon1600-01504831
nsc759818
AKOS005530658
pyrazinecarboxylic acid, 5-methyl-, 4-oxide
k9ay9ir2sd ,
5-carboxy-2-methylpyrazine 1-oxide
FT-0601589
S1806
BRD-K63736853-001-01-4
2-carboxy-5-methyl-pyrazine-4-oxide
CCG-213957
HY-B0283
SCHEMBL48922
MB01535
acipimox [inn]
acipimox [who-dd]
acipimox [mi]
5-methylpyrazine-2-carboxylic acid-4-oxide
acipimox [mart.]
NCGC00160519-03
W-105921
5-methyl-4-oxide-2-pyrazinecarboxylic acid
AB01274727_04
AB01274727_03
mfcd00865757
CHEBI:94688
HMS3655A14
SR-05000001505-1
sr-05000001505
SR-05000001505-2
HMS3713L18
SW199084-2
DB09055
4-oxo-5-methyl-2-pyrazinecarboxylicacid
AS-15565
k-9321;olbemox;olbetam; k9321; k 9321
BCP28412
Q2342544
5-carboxy-2-methylpyrazine1-oxide
BA166874
5-carboxy-2-methylpyrazin-1-ium-1-olate
EN300-151913
Z1198155438

Research Excerpts

Overview

Acipimox seems to be a useful agent for treatment of diabetic dyslipidemia and does not deteriorate glycemic control. The acipimx/GHRH test is a potential additional tool to detect GH deficiency in patients with pituitary disease.

ExcerptReferenceRelevance
"Acipimox is an analog of nicotinic acid and is indicated for the treatment of dyslipidemia. "( The assessment of human regional drug absorption of free acid and sodium salt forms of acipimox, in healthy volunteers, to direct modified release formulation strategy.
Cefali, E; Connor, A; Menon, R; Wilding, I; Wray, H, 2009
)
2.02
"Acipimox is a nicotinic acid-derived antilipolytic drug devoid of major side effects, and has been used in a number of human trials. "( Acipimox stimulates leptin production from isolated rat adipocytes.
Guo, W; Han, J; Wang-Fisher, YL, 2002
)
3.2
"The acipimox/GHRH test is a potential additional tool to detect GH deficiency in patients with pituitary disease, in particular in patients with a perturbation of fatty acid metabolism."( Diagnosis of growth hormone deficiency after pituitary surgery: the combined acipimox/GH-releasing hormone test.
Casanueva, FF; Cordido, F; de Vries, WR; Dieguez, C; Koppeschaar, HP; van Dam, PS; van Thiel, E; Veldhuyzen, BF, 2003
)
1.03
"Acipimox is an antilipolytic drug that produces an acute reduction of free fatty acids (FFA)."( Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
Alvarez, P; Casanueva, FF; Cordido, F; Dieguez, C; Isidro, L; Leal-Cerro, A; Peinó, R, 2003
)
1.29
"Acipimox is a new potent nicotinic acid derivative that rapidly reduces serum free fatty acid (FFA) levels by inhibiting lipolysis in peripheral tissue."( Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative.
Bergman, J; Haaparanta, M; Härkönen, R; Hartiala, J; Knuuti, MJ; Mäki, M; Nuutila, P; Ruotsalainen, U; Teräs, M; Voipio-Pulkki, LM; Wegelius, U; Yki-Järvinen, H, 1994
)
1.01
"Acipimox seems to be a useful agent for treatment of diabetic dyslipidemia and does not deteriorate glycemic control."( Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.
Babic, D; Cvrkalová, AL; Klimes, I; Koev, D; Langrová, H; Profozic, V; Rajecová, E; Skrabalo, Z; Susic, M; Zlateva, S, 1993
)
1.94
"Acipimox is a nicotinic acid like lipid lowering drug with less side-effects."( The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Birkenhäger, JC; De Heide, L; Deckers, JW; Hoogerbrugge, N; Jansen, H; Zillikens, MC, 1997
)
1.32
"Acipimox is a nicotinic acid like lipid lowering drug with less side-effects."( The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Birkenhäger, JC; De Heide, L; Deckers, JW; Hoogerbrugge, N; Jansen, H; Zillikens, MC, 1998
)
1.32
"Acipimox is a nicotinic-acid derivative that reduces serum free fatty acid (FFA) levels and enhances myocardial glucose uptake."( Acipimox does not augment thallium-201 redistribution in the fasting state.
Bomanji, J; Clunie, G; Eastick, S; Ell, PJ; Gunning, MG; Underwood, SR; Yepes-Mora, S,
)
2.3
"Acipimox is a hypolipidaemic agent reducing serum concentrations of triglycerides and non-esterified fatty acids. "( Effects of acipimox on the lipolysis rate in subcutaneous adipose tissue of obese subjects.
Adler, G; Alt, A; Ditschuneit, HH; Flechtner-Mors, M; Jenkinson, CP,
)
1.96

Actions

Acipimox blunted the increase in glucose after oral glucose loading and decreased incremental glucose concentration. It also decreased incremental insulin concentration (from 13.4 +/- 2.5 to 9.0 +/- 1.4 U/min/L, P = .056) in the OGTT.

ExcerptReferenceRelevance
"Acipimox tended to increase glucose and decrease lipid utilization rates at the whole body level and significantly changed the effect of insulin on substrate utilization."( Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function.
Bøtker, HE; Eiskjær, H; Gøtzsche, L; Halbirk, M; Møller, N; Nielsen, R; Nielsen, SS; Nielsen, TT; Nielsen-Kudsk, JE; Nørrelund, H; Schmitz, O; Wiggers, H, 2010
)
1.34
"Acipimox blocked the increase in plasma NEFA concentrations and almost completely repressed any rise in ERK1/2 and p38 but not in JNK."( Contribution of nonesterified fatty acids to mitogen-activated protein kinase activation in human skeletal muscle during endurance exercise.
Deldicque, L; Francaux, M; Raymackers, JM; van Loon, LJ; Zbinden-Foncea, H, 2013
)
1.11
"Acipimox abolished the increase in the nonesterified fatty acid (NEFA) concentration observed during the run after placebo and reduced lipid oxidation (placebo, 37 +/- 7 g; acipimox, 21 +/- 3 g; P < .05, mean +/- SEM), but had no effect on gross energy expenditure (placebo, 4.86 +/- 0.20 MJ; acipimox, 4.83 +/- 0.18 MJ)."( The reduction in postprandial lipemia after exercise is independent of the relative contributions of fat and carbohydrate to energy metabolism during exercise.
Bowness, RJ; Hardman, AE; Macdonald, IA; Malkova, D, 1999
)
1.02
"Acipimox blunted the increase in glucose after oral glucose loading and decreased incremental glucose concentration (from 579 +/- 76 to 445 +/- 65 mmol/min/L, P less than .02) and incremental insulin concentration (from 13.4 +/- 2.5 to 9.0 +/- 1.4 U/min/L, P = .056) in the OGTT."( Effect of acute inhibition of lipolysis on operation of the glucose-fatty acid cycle in hepatic cirrhosis.
Alberti, KG; Farrer, M; Fulcher, GR; Johnson, AJ; Record, CO, 1992
)
1

Treatment

Acipimox treatment prevented IH-induced lipolysis and increased epididymal fat mass and adipocyte size by 19 and 10%, respectively. Acipimx treatment reduced basal FFA rate of appearance by 68.9% (95% CI 52.6-79.5)

ExcerptReferenceRelevance
"Acipimox treatment increases systemic GLP-1 levels in both obese subjects and hypopituitary patients. "( Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.
Gribble, FM; Hjelholt, AJ; Holst, JJ; Jessen, N; Jørgensen, JOL; Kuhre, RE; Larraufie, P; Møller, N; Reimann, F; Vestergaard, ET, 2019
)
3.4
"Acipimox treatment increased plasma NEFA levels (759 ± 44 vs."( Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans.
Auwerx, J; Bierwagen, A; Bilet, L; Havekes, B; Hesselink, MK; Hwang, JH; Livingstone, R; Moullan, N; Nowotny, P; Paglialunga, S; Phielix, E; Pirinen, E; Roden, M; Ropelle, ER; Schrauwen, P; Schrauwen-Hinderling, VB; Sparks, LM; Szendroedi, J; van de Weijer, T; Williams, EG, 2015
)
1.39
"Acipimox treatment prevented IH-induced lipolysis and increased epididymal fat mass and adipocyte size by 19 and 10%, respectively."( Inhibition of Lipolysis Ameliorates Diabetic Phenotype in a Mouse Model of Obstructive Sleep Apnea.
Koc, M; Polak, J; Seda, O; Shimoda, LA; Weiszenstein, M, 2016
)
1.16
"Acipimox treatment resulted in a significant increase in the insulin sensitivity index (acipimox = 1.63 +/- 0.5 compared with placebo = 0.88 +/- 0.3 x 10(-4) x min(-1) x micro IU/mL, P = 0.015)."( Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution.
Aliabadi, N; Breu, J; Grinspoon, S; Hadigan, C; Meininger, G; Rabe, J, 2003
)
1.04
"Acipimox treatment reduced basal FFA rate of appearance by 68.9% (95% CI 52.6-79.5) and decreased plasma FFA concentration by 51.6% (42.0-58.9) (both, P < 0.0001)."( Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy.
Ditlevsen, S; Frøsig, C; Lindegaard, B; Mittendorfer, B; Pedersen, BK; Petersen, AM; Plomgaard, P; Van Hall, G; Wojtaszewski, JF, 2007
)
1.06
"The acipimox and placebo treatments were separated by a 2-week washout period."( Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
Beck-Nielsen, H; Henriksen, JE; Melander, A; Thye-Rønn, P; Vaag, A; Worm, D, 1994
)
1.01
"Acipimox treatment led to a significant drop in fasting serum total triglyceride levels (by 28%) after 1 mo of drug administration. "( Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.
Babic, D; Cvrkalová, AL; Klimes, I; Koev, D; Langrová, H; Profozic, V; Rajecová, E; Skrabalo, Z; Susic, M; Zlateva, S, 1993
)
1.94
"Acipimox treatment, produced significantly lower fat oxidation (36.9 +/- 12.8% vs 50.2 +/- 16.1%, P = 0.011), and lower plasma concentrations of FFA and glycerol (P = < 0.0001 and P = < 0.0001, respectively)."( The impact of a short course of three lipid lowering drugs on fat oxidation during exercise in healthy volunteers.
Cramb, R; Head, A; Jakeman, PM; Kendall, MJ; Maxwell, S, 1993
)
1.01
"Acipimox pretreatment alone (n = 6) induced a reduction in FFA levels compared with placebo treatment."( Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
Alvarez, CV; Casanueva, FF; Cordido, F; Dieguez, C; Peino, R; Peñalva, A, 1996
)
2.46
"Acipimox pretreatment alone (n = 13) induced a large reduction in FFA levels compared with placebo treatment."( Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Alvarez, CV; Casanueva, FF; Cordido, F; Dieguez, C; Peino, R; Peñalva, A, 1996
)
1.24
"Acipimox treatment increased the acute insulin response (AIR) in hyperthyroid patients (943 +/- 381 v 698 +/- 279 microU/mL x min, P < .05), whereas it did not change the AIR in controls."( Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients.
Cho, BY; Kim, CH; Kim, SY; Lee, HK; Lee, MK; Park, DJ; Park, KS; Shin, CS, 1999
)
1.26
"Treatment with ACIPIMOX transiently decreased plasma free fatty acids, glucose and insulin and increased valine plasma levels, and had no long-term effect on food consumption and body weight."( Anti-aging effects of anti-lipolytic drugs.
Bergamini, E; Carresi, C; Cavallini, G; Donati, A; Gori, Z; Parentini, I, 2004
)
0.66
"They treated with acipimox 15 patients who suffered from non-insulin-dependent diabetes mellitus, as well as II/B, IV type hyperlipoproteinaemia by Fredrickson."( [Effect of acipimox on diabetes mellitus-associated hyperlipoproteinemia].
Balogh, Z; Boda, J; Juhász, A; Leövey, A; Mohácsi, A; Paragh, G, 1993
)
1
"Treatment with acipimox resulted in complete suppression of NEFA levels and in a markedly higher GLP-1 response than the response to carbohydrate alone or to carbohydrate plus heparin."( Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids.
Marks, V; Morgan, L; Norris, F; Ranganath, L; Wright, J, 1999
)
0.64
"Treatment with acipimox (10 mg/kg), an anti-lipolytic agent, before or after amylin infusion blocked amylin's effects on plasma NEFA, glycerol, and insulin but not on glucose and lactate."( Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance.
Choong, B; Cooney, GJ; Cooper, GJ; Iglesias, MA; Kraegen, EW; Lim-Fraser, M; Watson, DG; Ye, JM, 2001
)
0.65

Toxicity

Cardiac FDG single photon emission computed tomography after Acipimox is a simple and safe approach that renders comparable image quality to that obtained during hyperinsulinemic euglycemic clamping.

ExcerptReferenceRelevance
" If the impairment of cellular cholesterol efflux to plasma is sustained with long-term treatment, this potentially adverse effect should be considered when treating diabetic dyslipidaemia with Acipimox."( Short-term Acipimox decreases the ability of plasma from Type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux: a potentially adverse effect on reverse cholesterol transport.
Dullaart, RP; van Tol, A, 2001
)
0.89
"Cardiac FDG single photon emission computed tomography after Acipimox is a simple and safe approach that renders comparable image quality to that obtained during hyperinsulinemic euglycemic clamping."( Safety and feasibility of cardiac FDG SPECT following oral administration of Acipimox, a nicotinic acid derivative: Comparison of image quality with hyperinsulinemic euglycemic clamping in nondiabetic patients.
Bax, JJ; Boersma, E; Elhendy, A; Poldermans, D; Sloof, GW; Van Lingen, A; Visser, CA; Visser, FC,
)
0.6

Pharmacokinetics

Acipimox plasma levels, monitored during the study, proved in agreement with those expected on a theoretical pharmacokinetic basis. Mean maximum concentration, the corresponding time, area under the curve extrapolated to infinity and elimination half-life values were equal to 5.

ExcerptReferenceRelevance
" Acipimox plasma levels, monitored during the study, proved in agreement with those expected on a theoretical pharmacokinetic basis."( A pilot study of the pharmacokinetics and triglyceride lowering activity of acipimox in dialyzed uremic patients.
Bonadonna, A; Bruno, R; Cascone, C; De Luca, M; Maggi, E; Munaretto, G; Tamassia, V, 1985
)
1.41
" After a single dose administration of sustained-release tablets and capsules, the pharmacokinetic parameters were as follows: AUC were (158 +/- 30) and (147 +/- 37) microg x h x mL(-1); Tmax were (4."( [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
Bai, HJ; Nie, SF; Pan, WS; Yang, XG; Zhang, GJ, 2005
)
0.59
" The Cmax of sustained-release tablet was lower than that of capsules, while the Tmax and MRT of sustained-release tablet were higher than that of capsule, which indicating a good retarding effect."( [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
Bai, HJ; Nie, SF; Pan, WS; Yang, XG; Zhang, GJ, 2005
)
0.59
"The study was designed to compare the pharmacokinetic parameters and relative bioavailability of a newly generic acipimox 250-mg tablets (test formulation) with a branded 250-mg tablets (reference formulation)."( Pharmacokinetics and bioequivalence evaluation of two acipimox tablets: a single-dose, randomized-sequence, two-way crossover study in healthy Chinese male volunteers.
Chen, R; Guo, R; Huang, J; Li, R; Liu, X; Wang, B; Wei, C; Yuan, G, 2013
)
0.85
"0 was used to calculate the pharmacokinetic parameters and assess bioequivalence of the 2 formulations."( Pharmacokinetics and bioequivalence evaluation of two acipimox tablets: a single-dose, randomized-sequence, two-way crossover study in healthy Chinese male volunteers.
Chen, R; Guo, R; Huang, J; Li, R; Liu, X; Wang, B; Wei, C; Yuan, G, 2013
)
0.64
"No period, formulation, or sequence effects were observed on any pharmacokinetic parameters."( Pharmacokinetics and bioequivalence evaluation of two acipimox tablets: a single-dose, randomized-sequence, two-way crossover study in healthy Chinese male volunteers.
Chen, R; Guo, R; Huang, J; Li, R; Liu, X; Wang, B; Wei, C; Yuan, G, 2013
)
0.64
" The method was then successfully applied in a pharmacokinetic comparison between normoxic and hypoxic rats."( Quantification of Acipimox in Plasma and Tissues by LC-MS/MS: Application to Pharmacokinetic Comparison between Normoxia and Hypoxia.
Deng, H; Gao, Y; Lai, C; Li, G; Shen, X; Wang, L; Wang, N; Yu, H; Zhou, L; Zhou, W, 2022
)
1.06

Compound-Compound Interactions

ExcerptReferenceRelevance
" To clarify their role, we studied the influence of inhibition of plasma FFA levels, induced by 500 mg oral acipimox (ACX), an antilipolytic drug, on the GH response to GH-releasing hormone (GHRH) alone or combined with arginine ([ARG] study A) in six normal women ([NS] aged 24 to 37 years; body mass index, 22."( Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
Boffano, GM; Camanni, F; Ghigo, E; Grottoli, S; Maccario, M; Oleandri, SE; Procopio, M; Taliano, M, 1996
)
0.9
" We hypothesize that nicotine when combined with a high-fat diet (HFD) can also cause ectopic lipid accumulation in skeletal muscle, similar to recently observed hepatic steatosis."( Nicotine in combination with a high-fat diet causes intramyocellular mitochondrial abnormalities in male mice.
Friedman, TC; Ivey, R; Lee, D; Shin, CS; Sinha-Hikim, AP; Sinha-Hikim, I, 2014
)
0.4

Bioavailability

The study was designed to compare the pharmacokinetic parameters and relative bioavailability of a newly generic acipimox 250-mg tablets. The purpose of this study was to direct modified release (MR) formulation strategy.

ExcerptReferenceRelevance
" In the second trial the effect of food on the drug bioavailability and pharmacokinetics during repeated administration was investigated in six volunteers."( Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent.
Maggi, E; Moro, E; Musatti, L; Tamassia, V; Valzelli, G, 1981
)
0.52
" The purpose of this study was to direct modified release (MR) formulation strategy by comparing the bioavailability of two forms of acipimox (free acid and sodium salt) from the distal small bowel (DSB) and colon with an immediate release formulation."( The assessment of human regional drug absorption of free acid and sodium salt forms of acipimox, in healthy volunteers, to direct modified release formulation strategy.
Cefali, E; Connor, A; Menon, R; Wilding, I; Wray, H, 2009
)
0.78
"The study was designed to compare the pharmacokinetic parameters and relative bioavailability of a newly generic acipimox 250-mg tablets (test formulation) with a branded 250-mg tablets (reference formulation)."( Pharmacokinetics and bioequivalence evaluation of two acipimox tablets: a single-dose, randomized-sequence, two-way crossover study in healthy Chinese male volunteers.
Chen, R; Guo, R; Huang, J; Li, R; Liu, X; Wang, B; Wei, C; Yuan, G, 2013
)
0.85
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Acipimox was given at the dosage of one capsule (250 mg), two or three times daily for at least 2 months. The free fatty acid concentrations were significantly higher on day 4 compared with day 1.

ExcerptRelevanceReference
" These results demonstrate the effectiveness of such a well tolerated low dosage combination therapy."( Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
Bedford, DK; Gaw, A; Kilday, C; Lorimer, AR; Packard, CJ; Series, JJ; Shepherd, J, 1990
)
1.72
" Acipimox was given at the dosage of one capsule (250 mg), two or three times daily for at least 2 months."( Results of a phase IV study carried out with acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia.
Lavezzari, M; Milanesi, G; Oggioni, E; Pamparana, F,
)
1.3
" Accordingly, a dosage schedule of 50 mg or 100 mg of acipimox after each dialysis session was selected for a second, 4-week study in 14 uremic patients with hypertriglyceridemia."( A pilot study of the pharmacokinetics and triglyceride lowering activity of acipimox in dialyzed uremic patients.
Bonadonna, A; Bruno, R; Cascone, C; De Luca, M; Maggi, E; Munaretto, G; Tamassia, V, 1985
)
0.75
" Mean area under the curve over one dosing interval (8 h) and elimination half-life values of acipimox after repeated dosing were not significantly different from the corresponding values after the single dose."( Pharmacokinetics of acipimox and of its N-deoxy metabolite following single and repeated oral administration to healthy volunteers.
Basileo, G; Efthymiopoulos, C; Musatti, L; Poggesi, I; Ruff, F; Strolin Benedetti, M,
)
0.67
" Effects of GPR109A agonists on lipolysis were measured in both species after oral dosing of compounds, and measuring plasma levels of free fatty acids."( Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.
Carballo-Jane, E; Colletti, SL; Forrest, MJ; Gerckens, LS; Luell, S; McCann, ME; Parlapiano, AS; Richman, JG; Taggart, AK; Tata, JR; Waters, MG; Wolff, M,
)
0.13
" We therefore aimed at describing dose-response relationships between amino acid metabolism and circulating FFA concentrations at clamped hormone levels."( Dose-response effects of free fatty acids on amino acid metabolism and ureagenesis.
Christiansen, JS; Gjedde, S; Gjedsted, J; Gormsen, LC; Jørgensen, JO; Møller, N; Nørrelund, H; Schmitz, O, 2008
)
0.35
"8 kg/m(2)) received either placebo or acipimox 250 mg three times daily dosage for 2 weeks."( Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans.
Auwerx, J; Bierwagen, A; Bilet, L; Havekes, B; Hesselink, MK; Hwang, JH; Livingstone, R; Moullan, N; Nowotny, P; Paglialunga, S; Phielix, E; Pirinen, E; Roden, M; Ropelle, ER; Schrauwen, P; Schrauwen-Hinderling, VB; Sparks, LM; Szendroedi, J; van de Weijer, T; Williams, EG, 2015
)
0.94
" The results provide important and valuable information for the safety and efficacy of acipimox, which indicated that the dosage of acipimox might be adjusted appropriately during clinical medication in hypoxia."( Quantification of Acipimox in Plasma and Tissues by LC-MS/MS: Application to Pharmacokinetic Comparison between Normoxia and Hypoxia.
Deng, H; Gao, Y; Lai, C; Li, G; Shen, X; Wang, L; Wang, N; Yu, H; Zhou, L; Zhou, W, 2022
)
1.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrazinecarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
AR proteinHomo sapiens (human)Potency0.66820.000221.22318,912.5098AID743042
EWS/FLI fusion proteinHomo sapiens (human)Potency30.09070.001310.157742.8575AID1259252; AID1259253; AID1259256
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
Cellular tumor antigen p53Homo sapiens (human)Potency7.49780.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hydroxycarboxylic acid receptor 2Homo sapiens (human)EC50 (µMol)5.30000.00871.20176.3096AID281255
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (170)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
neutrophil apoptotic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
positive regulation of neutrophil apoptotic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
negative regulation of lipid catabolic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
positive regulation of adiponectin secretionHydroxycarboxylic acid receptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayHydroxycarboxylic acid receptor 2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (58)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
nicotinic acid receptor activityHydroxycarboxylic acid receptor 2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneHydroxycarboxylic acid receptor 2Homo sapiens (human)
cell junctionHydroxycarboxylic acid receptor 2Homo sapiens (human)
plasma membraneHydroxycarboxylic acid receptor 2Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID143599Concentration required for inhibition of free fatty acid liberation in Canine myocardial lipase assay1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Synthesis and antilipolytic activities of quinolyl carbanilates and related analogues.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID281257Activity at GPR109b in CHO cells assessed as inhibition of forskolin-induced cAMP generation upto 30 uM2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID281258Activity at GPR109b in CHO cells assessed as inhibition of forskolin-induced cAMP generation upto 100 uM2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
AID281255Activity at GPR109a in CHO cells assessed as inhibition of forskolin-induced cAMP generation2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
AID1346416Human HCA2 receptor (Hydroxycarboxylic acid receptors)2003Biochemical and biophysical research communications, Mar-28, Volume: 303, Issue:1
Molecular identification of nicotinic acid receptor.
AID1346416Human HCA2 receptor (Hydroxycarboxylic acid receptors)2003The Journal of biological chemistry, Mar-14, Volume: 278, Issue:11
Molecular identification of high and low affinity receptors for nicotinic acid.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (269)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (8.55)18.7374
1990's120 (44.61)18.2507
2000's72 (26.77)29.6817
2010's39 (14.50)24.3611
2020's15 (5.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.63 (24.57)
Research Supply Index6.05 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index66.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials140 (49.47%)5.53%
Reviews9 (3.18%)6.00%
Case Studies7 (2.47%)4.05%
Observational0 (0.00%)0.25%
Other127 (44.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin [NCT01209416]8 participants (Anticipated)Interventional2012-06-30Completed
Lipolytic Effects of GH in Hypopituitary Patients in Vivo: Molecular Mechanisms and Temporal Patterns. [NCT02782208]9 participants (Actual)Interventional2016-02-10Completed
Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise [NCT01260376]9 participants (Actual)Interventional2011-04-30Completed
A Randomised, Open Label, Four-way Crossover Phase I Trial to Investigate the in Vivo Specificity of a Single Oral Dose of 320 mg KUC 7483 CL Co-administered With Bisoprolol (10 mg Daily), Propranolol (160 mg Daily), and Acipimox (500 mg Daily) Over 5 Day [NCT02256722]Phase 112 participants (Actual)Interventional2005-10-31Completed
Role of Lipotoxicity in Insulin Resistance, Vascular, and Mitochondrial Dysfunction in Type 1 Diabetes [NCT01816165]Phase 328 participants (Actual)Interventional2011-06-30Completed
Effects of Serum Fatty Acid Lowering on Insulin Sensitivity, Cardiovascular Function, And Exercise Capacity in Non-Insulin Dependent Diabetes [NCT01580813]13 participants (Actual)Interventional2011-06-30Completed
Assessing the Effects of Increased Mitochondrial Function and Chronic Aerobic or Resistance Exercise Training on Skeletal Muscle Performance in Older Men; a Pilot Study [NCT03325491]2 participants (Actual)Interventional2018-03-07Terminated(stopped due to Challenges recruiting healthy, sedentary 65-75 year old males)
Anti-Lipolytic Strategy for HIV Lipodystrophy [NCT00246402]30 participants Interventional2002-09-30Completed
The Effect of Acipimox on GLP-1 Secretion in Healthy Subjects: a Pilot Study [NCT02796950]8 participants (Actual)Interventional2016-06-30Completed
Assessing the Effects of Increased Mitochondrial Function on Skeletal Muscle Performance in Older Men; a Pilot Study [NCT02792621]16 participants (Actual)Interventional2016-11-08Completed
The Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function [NCT00943059]31 participants (Actual)Interventional2010-03-31Completed
Effect of 4 Weeks Treatment With Acipimox on Left Ventricular Function, Work Capacity, Insulin Sensitivity and Substrate Metabolism in Patients With Chronic Heart Failure [NCT00549614]28 participants (Anticipated)Interventional2007-10-31Completed
Acipimox Administration Together With Short-Term Exercise Exerts A Co-Feedback of Growth Hormone, Pancreatic Polypeptide, Peptide YY and Leptin on Ghrelin in Young Bulimic Czech Women: A Randomized Study [NCT03338387]Phase 224 participants (Anticipated)Interventional2003-05-06Enrolling by invitation
Metabolic Modulation as Treatment in Acute Heart Failure [NCT00449423]Phase 232 participants (Anticipated)Interventional2007-03-31Terminated(stopped due to due to slow recruitment)
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome [NCT00759291]Phase 2/Phase 340 participants (Actual)Interventional2006-04-01Completed
The Impact of Free Fatty Acid Reduction on Vascular Function and Skeletal Muscle Glucose Utilization in Type 2 Diabetes Mellitus [NCT00153179]Phase 1/Phase 240 participants (Actual)Interventional2005-09-30Completed
HYPOglycemia Linked to Cardiac sTEatoSIS? - Identifying Mechanisms That Explain Adverse Cardiovascular Outcome Associated With Intensive Glucose Control in Patients With Diabetes (HYPOTESIS) [NCT01980524]Phase 2/Phase 38 participants (Actual)Interventional2013-10-31Completed
The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity [NCT01488409]Phase 239 participants (Actual)Interventional2012-05-31Completed
Can the Health Benefits of a Walking-based Exercise Programme be Enhanced by Co-ingestion of a Lipid-lowering Drug? [NCT03809793]34 participants (Anticipated)Interventional2020-01-06Suspended(stopped due to COVID-19)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00153179 (1) [back to overview]Flow-mediated Dilation After Placebo or Acipimox Treatment Between Healthy Controls and Those With Metabolic Syndrome
NCT00759291 (1) [back to overview]Flow Mediated Vasodilation
NCT01488409 (5) [back to overview]Change From Baseline in Phosphocreatine Recovery (ViPCr) at 6-months
NCT01488409 (5) [back to overview]Change From Baseline in Insulin Sensitivity at 6-months
NCT01488409 (5) [back to overview]Change From Baseline in Mitochondrial Density at 6 Months
NCT01488409 (5) [back to overview]Change From Baseline in Lipid Profile at 6-months
NCT01488409 (5) [back to overview]Change From Baseline in Intramyocellular Lipid Content at 6-months
NCT01580813 (9) [back to overview]Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: Peak Heart Rate
NCT01580813 (9) [back to overview]Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: Peak VO2
NCT01580813 (9) [back to overview]Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: VO2 Kinetics
NCT01580813 (9) [back to overview]Evaluating the Effect of Acipimox on Insulin Sensitivity and Cardiovascular Function: Cardiac Function
NCT01580813 (9) [back to overview]Evaluating the Effect of Acipimox on Insulin Sensitivity and Cardiovascular Function: Endothelial Function
NCT01580813 (9) [back to overview]Evaluating the Effect of Acipimox on Insulin Sensitivity and Cardiovascular Function: Inflammation
NCT01580813 (9) [back to overview]Insulin Sensitivity
NCT01580813 (9) [back to overview]Triglycerides
NCT01580813 (9) [back to overview]Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: Power Output at Anaerobic Threshold and at Peak Exercise
NCT01816165 (16) [back to overview]Arterial Stiffness (AI)
NCT01816165 (16) [back to overview]Arterial Stiffness (PWV)
NCT01816165 (16) [back to overview]Heart Rate Variability
NCT01816165 (16) [back to overview]Insulin Sensitivity: M-value From Hyperinsulinemic Euglycemia Clamp Study
NCT01816165 (16) [back to overview]Metabolic Markers: Glycerol
NCT01816165 (16) [back to overview]Metabolic Markers: Insulin
NCT01816165 (16) [back to overview]Oxidative Stress and Inflammatory Markers: Adiponectin
NCT01816165 (16) [back to overview]Oxidative Stress and Inflammatory Markers: High-sensitivity C-reactive Protein (hsCRP)
NCT01816165 (16) [back to overview]Oxidative Stress and Inflammatory Markers: Interleukin 6 (IL6)
NCT01816165 (16) [back to overview]State 3 Mitochondrial Oxygen Consumption
NCT01816165 (16) [back to overview]Metabolic Markers: Mean 24 Hour Triglyceride and Glucose Levels
NCT01816165 (16) [back to overview]Metabolic Markers: Continuous Glucose Monitoring Measures
NCT01816165 (16) [back to overview]Vascular Markers
NCT01816165 (16) [back to overview]Percent Flow-mediated Brachial Artery Dilation
NCT01816165 (16) [back to overview]Oxidative Stress and Inflammatory Markers: TNFalpha
NCT01816165 (16) [back to overview]24 Hour Mean Fatty Acid Levels
NCT01980524 (3) [back to overview]Ejection Fraction
NCT01980524 (3) [back to overview]MYCL
NCT01980524 (3) [back to overview]Stroke Volume

Flow-mediated Dilation After Placebo or Acipimox Treatment Between Healthy Controls and Those With Metabolic Syndrome

Flow mediated dilation is calculated as follows: A resting arterial diameter measurement is obtained using the average of 10 EKG-gated ultrasound images. Next, an occlusive pressure is applied (using a blood pressure cuff inflated to a suprasystolic pressure)for a period of 5 minutes. After 5 minutes, the cuff is rapidly deflated. This produces a reactive hyperemic response which is captured via ultrasound at 1 minute post cuff deflation (also 10 EKG-gated images averaged). The diameter of the artery following reactive hyperemia is calculated and compared to the resting diameter to obtain a percent dilation. This is flow-mediated dilation. (NCT00153179)
Timeframe: 7 days

InterventionFlow mediated dilation (Mean)
Healthy Controls, Placebo Treatment10.65
Healthy Controls, Acipimox Treatment11.57
Metabolic Syndrome, Placebo Treatment8.79
Metabolic Syndrome, Acipimox Treatment9.52

[back to top]

Flow Mediated Vasodilation

Brachial artery response to a 5 minute blood pressure cuff-applied ischemic period (NCT00759291)
Timeframe: After 7 days of each treatment.

,
Interventionpercentage of vasodilation (Mean)
PlaceboAcipimox
Control10.810.9
Metabolic Syndrome9.510.5

[back to top]

Change From Baseline in Phosphocreatine Recovery (ViPCr) at 6-months

The rate of recovery of phosphocreatine concentration after depletion by exercise is considered a measurement of mitochondrial function. Change in phosphocreatine recovery from baseline to 6 months will therefore give a measurement of change in mitochondrial function. ViPCR is given -- a higher value indicates better mitochondrial function. (NCT01488409)
Timeframe: Change from Baseline to 6-months Visit

InterventionmM/s (Mean)
Acipimox1.7
Placebo1.6

[back to top]

Change From Baseline in Insulin Sensitivity at 6-months

Change in insulin resistance assessed by hyperinsulinemic-euglycemic clamp study at Baseline and at 6-months. Change in insulin-stimulated glucose uptake (M) during 40 mU/m2/min insulin clamp is given. (NCT01488409)
Timeframe: Change from Baseline to 6-months visit

Interventionmg/kg/min (Mean)
Acipimox0.1
Placebo0.2

[back to top]

Change From Baseline in Mitochondrial Density at 6 Months

Muscle tissue obtained from biopsy will be used to assess mitochondrial number and morphology by microscopes at Baseline and at 6-months. The change in mitochondrial density from 6 months to baseline is given. (NCT01488409)
Timeframe: Change from Baseline to 6-months

Interventionpercentage of total muscle fiber area (Mean)
Acipimox0.4
Placebo0

[back to top]

Change From Baseline in Lipid Profile at 6-months

Change in direct low density lipoprotein (LDL) cholesterol is given (NCT01488409)
Timeframe: Change from Baseline to 6-months

Interventionmg/dL (Mean)
Acipimox-19
Placebo6

[back to top]

Change From Baseline in Intramyocellular Lipid Content at 6-months

Change in tibialis intramyocellular lipid (IMCL) normalized to creatinine is given. (NCT01488409)
Timeframe: Change from Baseline to 6-months

Interventionratio of IMCL peak to Creatinine peak (Mean)
Acipimox-0.2
Placebo0.0

[back to top]

Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: Peak Heart Rate

Evaluate the impact of these effects of NEFA-lowering on exercise parameters, including VO2 kinetics, peak VO2, peak heart rate, peak power output. (NCT01580813)
Timeframe: 7 to 9 days

Interventionbeats/minute (Mean)
Acipimox148
Placebo149

[back to top]

Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: Peak VO2

Evaluate the impact of these effects of NEFA-lowering on exercise capacity measured as peak VO2. (NCT01580813)
Timeframe: 7 to 9 days

Interventionml/kg/min (Mean)
Acipimox19.7
Placebo18.2

[back to top]

Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: VO2 Kinetics

Evaluate the impact of these effects of NEFA-lowering VO2 kinetics as measured by tau2, the time required for VO2 to reach 67% of peak during submaximal exercise. (NCT01580813)
Timeframe: 7 to 9 days

Interventionseconds (Mean)
Acipimox51.4
Placebo53.3

[back to top]

Evaluating the Effect of Acipimox on Insulin Sensitivity and Cardiovascular Function: Cardiac Function

Test the hypothesis that lowering of endogenous non-essential fatty acids (NEFA) in diabetic adults will improve cardiac function: echo measurement of resting ejection fraction (NCT01580813)
Timeframe: 7 to 9 days

Interventionpercent (Mean)
Acipimox71.4
Placebo69.9

[back to top]

Evaluating the Effect of Acipimox on Insulin Sensitivity and Cardiovascular Function: Endothelial Function

Test the hypothesis that lowering of endogenous non-essential fatty acids (NEFA) in diabetic adults will improve endothelial function measured by flow mediated dilation of the brachial artery. (NCT01580813)
Timeframe: 7 to 9 days

Intervention% change (Mean)
Acipimox4.9
Placebo5.3

[back to top]

Evaluating the Effect of Acipimox on Insulin Sensitivity and Cardiovascular Function: Inflammation

effect of lowering of endogenous non-essential fatty acids (NEFA) in diabetic adults on inflammation (hsCRP) (NCT01580813)
Timeframe: 7 to 9 days

Interventionmg/L (Mean)
Acipimox3.4
Placebo4.3

[back to top]

Insulin Sensitivity

"Test the hypothesis that lowering of endogenous non-essential fatty acids (NEFA) in diabetic adults will improve insulin sensitivity measured as glucose disposal by hyperinsulinemic euglycemic clamp. Unit of measure is mg/kg of lean body mass/min/microIU of insulin/ml.~The unit of measure reflects the rate at which glucose needs to be infused to maintain a normal blood sugar in the setting of a given serum insulin level from an insulin infusion. As such, a higher number means more glucose was needed and indicates greater sensitivity to insulin." (NCT01580813)
Timeframe: 7 to 9 days

Interventionmg/kg LBM/min/micro IU insulin/ml (Mean)
Acipimox6.00
Placebo6.04

[back to top]

Triglycerides

(NCT01580813)
Timeframe: 7 to 9 days

Interventionmg/dl (Mean)
Acipimox99
Placebo134

[back to top]

Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: Power Output at Anaerobic Threshold and at Peak Exercise

Evaluate the impact of these effects of NEFA-lowering on exercise parameters, including VO2 kinetics, peak VO2, peak heart rate, peak power output. (NCT01580813)
Timeframe: 7 to 9 days

,
InterventionWatts (Mean)
power output at ATPower output at peak
Acipimox75.8138
Placebo65.7129

[back to top]

Arterial Stiffness (AI)

"Augmentation index by Sphygmacor is a measure of aortic arterial stiffness. AI@75 is the ratio of augmented pressure/pulse pressure adjusted to a heart rate of 75.~Higher values indicate stiffer vessels" (NCT01816165)
Timeframe: day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

Interventionratio (Mean)
T1D: Acipimox21.4
T1D: Placebo19.7
No T1D: Acipimox11.1
No T1D: Placebo12.4

[back to top]

Arterial Stiffness (PWV)

Pulse wave velocity by Sphygmacor as a measure of aortic stiffness in m/sec. Higher values reflect a stiffer vasculature. (NCT01816165)
Timeframe: day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

Interventionm/sec (Mean)
T1D: Acipimox9.24
T1D: Placebo9.91
No T1D: Acipimox6.97
No T1D: Placebo7.4

[back to top]

Heart Rate Variability

Measure of autonomic function; ratio of fastest to slowest heart rate during valsalva maneuver. (NCT01816165)
Timeframe: day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

Interventionratio (Mean)
T1D: Acipimox1.37
T1D: Placebo1.43
No T1D: Acipimox1.59
No T1D: Placebo1.69

[back to top]

Insulin Sensitivity: M-value From Hyperinsulinemic Euglycemia Clamp Study

"Evaluate the impact of Non esterified fatty acid (NEFA)-lowering on insulin sensitivity in T1D versus non-DM. Glucose infusion rate is reported normalized to lean body weight in kg and to final insulin concentration.~The unit of measure reflects the rate at which glucose needs to be infused to maintain a normal blood sugar in the setting of a given serum insulin level from an insulin infusion. As such, a higher number means more glucose was needed and indicates greater sensitivity to insulin." (NCT01816165)
Timeframe: day 8 of each of the 2 random order intervention phases; max 16 weeks post enrollment

Interventionmg/kg*minute*microIU/mL*100 (Mean)
T1 Diabetes, Acipimox4.65
T1 Diabetes, Placebo3.67
No T1 Diabetes, Acipimox8.8
No T1 Diabetes, Placebo9.05

[back to top]

Metabolic Markers: Glycerol

mean glycerol for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300). (NCT01816165)
Timeframe: day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

Interventionmicromoles/L (Mean)
T1 Diabetes, Acipimox86
T1 Diabetes, Placebo75
No T1 Diabetes, Acipimox63
No T1 Diabetes, Placebo69

[back to top]

Metabolic Markers: Insulin

mean insulin for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300). (NCT01816165)
Timeframe: day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

InterventionmicroIU/mL (Mean)
T1 Diabetes, Acipimox48
T1 Diabetes, Placebo47
No T1 Diabetes, Acipimox20
No T1 Diabetes, Placebo21

[back to top]

Oxidative Stress and Inflammatory Markers: Adiponectin

adiponectin (NCT01816165)
Timeframe: day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

Interventionmicrograms/mL (Mean)
T1 Diabetes, Acipimox11.6
T1 Diabetes, Placebo14.9
No T1 Diabetes, Acipimox7.3
No T1 Diabetes, Placebo5.8

[back to top]

Oxidative Stress and Inflammatory Markers: High-sensitivity C-reactive Protein (hsCRP)

high-sensitivity C-reactive protein (hsCRP) (NCT01816165)
Timeframe: day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

Interventionmg/L (Mean)
T1 Diabetes, Acipimox3.19
T1 Diabetes, Placebo1.98
No T1 Diabetes, Acipimox1.43
No T1 Diabetes, Placebo1.44

[back to top]

Oxidative Stress and Inflammatory Markers: Interleukin 6 (IL6)

Interleukin 6 (IL6) (NCT01816165)
Timeframe: day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

Interventionpicograms/mL (Mean)
T1 Diabetes, Acipimox2.8
T1 Diabetes, Placebo4.2
No T1 Diabetes, Acipimox2.6
No T1 Diabetes, Placebo3.5

[back to top]

State 3 Mitochondrial Oxygen Consumption

Measures skeletal muscle mitochondrial function and effects of acipimox thereon, carbohydrate & lipid substrates. State 3 is fully active coupled oxygen flux using PMG or PMGS (pyruvate, malate, glutamate, +/- succinate) or OCMS (octanyl carnitine, malate, +/- succinate) as substrates. FCCP is added as an uncoupler to measure maximum possible O2 flux. Higher values reflect better mitochondrial function. (NCT01816165)
Timeframe: muscle biopsy on day 7 of each weeklong intervention period; max 16 weeks post enrollment

,,,
Interventionpmoles/mg/s (Mean)
PMG State 3 Oxygen FluxPMGS State 3 Oxygen FluxPMGS Uncoupled Max Oxygen FluxOCM State 3 Oxygen FluxOCMS State 3 Oxygen FluxOCMS Uncoupled Max Oxygen Flux
No T1 Diabetes, Acipimox30.242.577.818.843.880.1
No T1 Diabetes, Placebo29.742.580.217.341.773.1
T1 Diabetes, Acipimox26.138.065.214.038.651.8
T1 Diabetes, Placebo24.936.962.115.038.556.4

[back to top]

Metabolic Markers: Mean 24 Hour Triglyceride and Glucose Levels

mean glucose and triglycerides for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300). (NCT01816165)
Timeframe: day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

,,,
Interventionmg/dL (Mean)
glucosetriglycerides
No T1 Diabetes, Acipimox8767
No T1 Diabetes, Placebo8983
T1 Diabetes, Acipimox13559
T1 Diabetes, Placebo13168

[back to top]

Metabolic Markers: Continuous Glucose Monitoring Measures

Continuous glucose monitoring measures for 3 days before clamp. Collected for participants with T1 Diabetes only. (NCT01816165)
Timeframe: day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

,
Interventionmmol/L (Mean)
Average GlucoseGlycemic Variability
T1D: Acipimox8.823.64
T1D: Placebo9.093.64

[back to top]

Vascular Markers

endothelin 1 measured as a marker of vascular damage (NCT01816165)
Timeframe: day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

Interventionpg/mL (Mean)
T1 Diabetes, Acipimox4.92
T1 Diabetes, Placebo4.9
No T1 Diabetes, Acipimox4.83
No T1 Diabetes, Placebo4.12

[back to top]

Percent Flow-mediated Brachial Artery Dilation

To determine the effects of NEFA lowering and insulin sensitization on endothelial function. Measures percent change in brachial artery diameter with hyperemia after occlusion. (NCT01816165)
Timeframe: day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

InterventionPercent change in BA diameter (Mean)
T1 Diabetes, Acipimox8.21
T1 Diabetes, Placebo8.82
No T1 Diabetes, Acipimox5.88
No T1 Diabetes, Placebo7.32

[back to top]

Oxidative Stress and Inflammatory Markers: TNFalpha

TNFalpha (NCT01816165)
Timeframe: day 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

Interventionpicograms/mL (Mean)
T1 Diabetes, Acipimox1.76
T1 Diabetes, Placebo1.71
No T1 Diabetes, Acipimox1.56
No T1 Diabetes, Placebo.91

[back to top]

24 Hour Mean Fatty Acid Levels

Assesses whether fatty acid level is consistently lowered by acipimox. Mean of fatty acid levels measured 22 times over 24 hours (hourly except 0100 and 0300 hours). (NCT01816165)
Timeframe: day 6 to 7 of each of the 2 random order intervention phases; max 16 weeks post enrollment

InterventionmicroEq/L (Mean)
T1 Diabetes, Acipimox343
T1 Diabetes, Placebo297
No T1 Diabetes, Acipimox298
No T1 Diabetes, Placebo335

[back to top]

Ejection Fraction

Left ventricular ejection fraction before and after administration of acipimox or placebo (NCT01980524)
Timeframe: 180 minutes

,
Interventionpercentage (Mean)
Baseline180 minutes after administration
Acipimox+7669
Placebo7877

[back to top]

MYCL

Intramyocardiocellular lipid content (MYCL) before and after administration of acipimox or placebo (NCT01980524)
Timeframe: 180 minutes

,
Interventionpercentage of water signal (Mean)
Baseline180 minutes after administration
Acipimox+0.540.35
Placebo0.440.36

[back to top]

Stroke Volume

Stroke volume before and after administration of acipimox or placebo (NCT01980524)
Timeframe: 180 minutes

,
Interventionml/m2 (Mean)
baseline180 minutes after administration
Acipimox+3831
Placebo3636

[back to top]